



ELSEVIER

Diabetes Research and Clinical Practice 40 (1998) 207–209

DIABETES RESEARCH  
AND  
CLINICAL PRACTICE

## Author index of volume 40

- Adachi, H., D.R. Jacobs, Jr., R. Hashimoto, M. Tsuruta, T. Imaizumi, Clustering of cardiovascular risk factors in hyperinsulinemia in Japanese without diabetes 40, 181
- Adeghate, E., see Ahmed, I. 40, 145
- Agardh, C.-D., see Agardh, D. 40, 9
- Agardh, C.-D., see Eckert, B. 40, 91
- Agardh, D., E. Agardh, M. Landin-Olsson, L.K. Gaur, C.-D. Agardh, Å. Lernmark, Inverse relationship between GAD65 antibody levels and severe retinopathy in younger type 1 diabetic patients 40, 9
- Agardh, E., see Agardh, D. 40, 9
- Ahmed, I., E. Adeghate, A.K. Sharma, D.J. Pallot, J. Singh, Effects of *Momordica charantia* fruit juice on islet morphology in the pancreas of the streptozotocin-diabetic rat 40, 145
- Ahmet Sivas, see Çakatay, U. 40, 75
- Akaike, N., see Yoshida, M. 40, 101
- Akçay, T., see Çakatay, U. 40, 75
- Altan, V.M., see Dinçer, Ü.D. 40, 113
- Aotsuka, T., see Yoshida, M. 40, 101
- Aral, F., see Çakatay, U. 40, 75
- Ari, N., see Dinçer, Ü.D. 40, 113
- Ashizawa, N., see Yoshida, M. 40, 101
- Bartelink, M.L., L. Hoek, J.P. Freriks, G.E. Rutten, Infections in patients with type 2 diabetes in general practice 40, 15
- Beilin, L.J., see Dunstan, D.W. 40, 53
- Bergström, A., see Wikblad, K. 40, 123
- Bouter, L.M., see Grootenhuys, P.A. 40, 81
- Brown, L.J., see Lunt, H. 40, 31
- Burke, V., see Dunstan, D.W. 40, 53
- Çakatay, U., A. Telci, R. Kayalı, T. Akçay, Ahmet Sivas, F. Aral, Changes in bone turnover on deoxypyridinoline levels in diabetic patients 40, 75
- Calogero, A.E., see Lunetta, M. 40, 45
- Cundy, T., see Lunt, H. 40, 31
- Delbachian, I., see Guerci, B. 40, 175
- Dinçer, Ü.D., A. Onay, N. Ari, A.T. Özçelikay, V.M. Altan, The effects of diabetes on  $\beta$ -adrenoceptor mediated responsiveness of human and rat atria 40, 113
- Drouin, P., see Guerci, B. 40, 175
- Dunstan, D.W., I.B. Puddey, L.J. Beilin, V. Burke, A.R. Morton, K.G. Stanton, Effects of a short-term circuit weight training program on glycaemic control in NIDDM 40, 53
- Eckert, B., E. Ryding, C.-D. Agardh, Sustained elevation of cerebral blood flow after hypoglycaemia in normal man 40, 91
- Elliot, J.R., see Lunt, H. 40, 31
- Florkowski, C.M., R.S. Scott, C.L. Moir, P.J. Graham, Clinical and biochemical outcomes of Type 2 diabetes mellitus in Canterbury, New Zealand: a 6-year cohort study 40, 167
- Florkowski, C.M., see Lunt, H. 40, 31
- Freriks, J.P., see Bartelink, M.L. 40, 15
- Fritsche, A., M. Stumvoll, W. Renn, R.-M. Schmülling, Diabetes teaching program improves glycemic control and preserves perception of hypoglycemia 40, 129
- Gaur, L.K., see Agardh, D. 40, 9
- Goswami, R., N. Jayasuryan, A. Jaleel, N. Tandon, N. Kochupillai, Insulin autoantibodies before and after carbimazole therapy in Asian Indian patients with Graves' disease 40, 201
- Graham, P.J., see Florkowski, C.M. 40, 167
- Grootenhuys, P.A., J.M. Mooy, P.J. Kostense, C. Popp-Snijders, L.M. Bouter, R.J. Heine, Dissimilar association of conventional immuno-reactive versus specific insulin with cardiovascular risk factors: a consequence of proinsulinaemia? 40, 81
- Guerci, B., L. Meyer, I. Delbachian, M. Kolopp, O. Ziegler, P. Drouin, Blood glucose control on Sunday in IDDM patients: intensified conventional insulin therapy versus continuous subcutaneous insulin infusion 40, 175
- Hashimoto, R., see Adachi, H. 40, 181


- Heine, R.J., see Grootenhuys, P.A. 40, 81  
 Hoek, L., see Bartelink, M.L. 40, 15  
 Hong, S.K., see Kim, C.-H. 40, 191
- Imaizumi, T., see Adachi, H. 40, 181  
 Inaba, M., K. Negishi, M. Takahashi, N. Serizawa, Y. Maruno, K. Takahashi, S. Katayama, Increased night:day blood pressure ratio in microalbuminuric normotensive NIDDM subjects 40, 161  
 Infantone, E., see Lunetta, M. 40, 45  
 Infantone, L., see Lunetta, M. 40, 45  
 Inoue, M., see Morishita, S. 40, 1
- Jacobs, D.R., Jr., see Adachi, H. 40, 181  
 Jaleel, A., see Goswami, R. 40, 201  
 Jayasuryan, N., see Goswami, R. 40, 201  
 Jeppsson, J.O., see Wikblad, K. 40, 123
- Karlsson, M.G., J. Ludvigsson, Determination of mRNA expression for IFN- $\gamma$  and IL-4 in lymphocytes from children with IDDM by RT-PCR technique 40, 21  
 Katayama, S., see Inaba, M. 40, 161  
 Kayali, R., see Çakatay, U. 40, 75  
 Kendall, D., see Lunt, H. 40, 31  
 Kim, C.-H., H.-K. Kim, J.Y. Park, H.S. Park, S.K. Hong, S.W. Park, K.-U. Lee, Association of microalbuminuria and atherosclerotic risk factors in non-diabetic subjects in Korea 40, 191  
 Kim, H.-K., see Kim, C.-H. 40, 191  
 Kochupillai, N., see Goswami, R. 40, 201  
 Kolopp, M., see Guerci, B. 40, 175  
 Kostense, P.J., see Grootenhuys, P.A. 40, 81
- Landin-Olsson, M., see Agardh, D. 40, 9  
 Lee, K.-U., see Kim, C.-H. 40, 191  
 Lernmark, Å., see Agardh, D. 40, 9  
 Ludvigsson, J., see Karlsson, M.G. 40, 21  
 Lunetta, M., L. Infantone, A.E. Calogero, E. Infantone, Increased urinary albumin excretion is a marker of risk for retinopathy and coronary heart disease in patients with type 2 diabetes mellitus 40, 45  
 Lunt, H., C.M. Florkowski, T. Cundy, D. Kendall, L.J. Brown, J.R. Elliot, J.E. Wells, J.G. Turner, A population-based study of bone mineral density in women with long-standing Type 1 (insulin dependent) diabetes 40, 31
- Manabe, M., see Morishita, S. 40, 1  
 Maruno, Y., see Inaba, M. 40, 161  
 Matsuura, A., see Yoshida, M. 40, 101  
 Merry, A.C., K. Yamamoto, A.A. Sima, Imbalances in N-CAM, SAM and polysialic acid may underlie the paranodal ion channel barrier defect in diabetic neuropathy 40, 153  
 Mertes, G., Efficacy and safety of acarbose in the treatment of Type 2 diabetes: data from a 2-year surveillance study 40, 63  
 Meyer, L., see Guerci, B. 40, 175
- Moir, C.L., see Florkowski, C.M. 40, 167  
 Mooy, J.M., see Grootenhuys, P.A. 40, 81  
 Morishita, S., E.F. Sato, K. Takahashi, M. Manabe, M. Inoue, Insulin-induced hypoglycemia elicits thymocyte apoptosis in the rat 40, 1  
 Morton, A.R., see Dunstan, D.W. 40, 53  
 Mugusi, F., see Wikblad, K. 40, 123
- Negishi, K., see Inaba, M. 40, 161
- Ohbayashi, S., see Yoshida, M. 40, 101  
 Onay, A., see Dinçer, Ü.D. 40, 113  
 Özçelikay, A.T., see Dinçer, Ü.D. 40, 113
- Pallot, D.J., see Ahmed, I. 40, 145  
 Park, H.S., see Kim, C.-H. 40, 191  
 Park, J.Y., see Kim, C.-H. 40, 191  
 Park, S.W., see Kim, C.-H. 40, 191  
 Polaschegg, E., Effect of physicochemical variables of regular insulin formulations on their absorption from the subcutaneous tissue 40, 39  
 Popp-Snijders, C., see Grootenhuys, P.A. 40, 81  
 Puddey, I.B., see Dunstan, D.W. 40, 53
- Renn, W., see Fritsche, A. 40, 129  
 Robertson, S.P., Simmons, D., Early childhood growth in ethnic groups predisposed to NIDDM: a prospective study 40, 137  
 Rutten, G.E., see Bartelink, M.L. 40, 15  
 Ryding, E., see Eckert, B. 40, 91
- Sato, E.F., see Morishita, S. 40, 1  
 Schmülling, R.-M., see Fritsche, A. 40, 129  
 Scott, R.S., see Florkowski, C.M. 40, 167  
 Serizawa, N., see Inaba, M. 40, 161  
 Sharma, A.K., see Ahmed, I. 40, 145  
 Sima, A.A., see Merry, A.C. 40, 153  
 Simmons, D., see P. Robertson, S. 40, 137  
 Singh, J., see Ahmed, I. 40, 145  
 Smide, B., see Wikblad, K. 40, 123  
 Stanton, K.G., see Dunstan, D.W. 40, 53  
 Stumvoll, M., see Fritsche, A. 40, 129  
 Sugiyama, Y., see Yoshida, M. 40, 101
- Takahashi, K., see Inaba, M. 40, 161  
 Takahashi, K., see Morishita, S. 40, 1  
 Takahashi, M., see Inaba, M. 40, 161  
 Tandon, N., see Goswami, R. 40, 201  
 Telci, A., see Çakatay, U. 40, 75  
 Tsuruta, M., see Adachi, H. 40, 181  
 Turner, J.G., see Lunt, H. 40, 31
- Wahren, L., see Wikblad, K. 40, 123  
 Wells, J.E., see Lunt, H. 40, 31  
 Wikblad, K., B. Smide, A. Bergström, L. Wahren, F. Mugusi, J.O. Jeppsson, Immediate assessment of HbA<sub>1c</sub> under field conditions in Tanzania 40, 123

Yamamoto, K., see Merry, A.C. **40**, 153

Yoshida, M., Y. Sugiyama, N. Akaike, N. Ashizawa, T.  
Aotsuka, S. Ohbayashi, A. Matsuura, Amelioration of neu-  
rovascular deficits in diabetic rats by a novel aldose reduc-

tase inhibitor, GP-1447: Minor contribution of nitric  
oxide **40**, 101

Ziegler, O., see Guerci, B. **40**, 175





ELSEVIER

Diabetes Research and Clinical Practice 40 (1998) 211–213

DIABETES RESEARCH  
AND  
CLINICAL PRACTICE

## Subject index of volume 40

**Acarbose**; Efficacy; Safety; Type 2 diabetes; Surveillance 40, 63

**$\beta$ -Adrenoceptors**; Diabetes; Rat right atria; Human atrial appendage 40, 113

**Aldose reductase inhibitor**; Motor nerve conduction velocity; Nitric oxide; Sciatic nerve blood flow 40, 101

**Apoptosis**; Hypoglycemia; Insulin; Thymocyte; Glucocorticoid 40, 1

**Asian Indians**; Graves' disease; Carbimazole; Insulin autoantibodies 40, 201

**Atherosclerotic risk factors**; Microalbuminuria; Insulin resistance syndrome 40, 191

**Blood glucose control**; IDDM; CSII; Intensive insulin therapy 40, 175

**Blood glucose estimation**; Type 1 diabetes; Teaching and treatment program; Blood glucose perception; Hypoglycemia awareness 40, 129

**Blood glucose perception**; Type 1 diabetes; Teaching and treatment program; Blood glucose estimation; Hypoglycemia awareness 40, 129

**Blood pressure monitoring**; Type 2 diabetes mellitus; Normotension; Microalbuminuria; Dipper; Non-dipper 40, 161

**Bone mineral density**; Osteopenia; Type 1 diabetes 40, 31

**Bone turnover**; Deoxypyridinoline; Diabetes; Osteocalcin 40, 75

**Carbimazole**; Graves' disease; Insulin autoantibodies; Asian Indians 40, 201

**Cardiovascular disease**; Hyperinsulinemia; Multiple risk factors 40, 181

**Cardiovascular risk factors**; Glucose tolerance; Insulin; Insulin resistance; Proinsulin 40, 81

**Cerebral blood flow**; Healthy subjects; Hypoglycemia recovery 40, 91

**Childhood growth**; Ethnic groups; Intrauterine environment; NIDDM 40, 137

**Coronary heart disease**; Diabetes mellitus type 2; Urinary albumin excretion; Diabetic retinopathy 40, 45

**CSII**; IDDM; Intensive insulin therapy; Blood glucose control 40, 175

**Deoxypyridinoline**; Bone turnover; Diabetes; Osteocalcin 40, 75

**Diabetes**;  $\beta$ -Adrenoceptors; Rat right atria; Human atrial appendage 40, 113

**Diabetes**; Bone turnover; Deoxypyridinoline; Osteocalcin 40, 75

**Diabetes**; Glycated haemoglobin; Method comparison; Tanzania 40, 123

**Diabetes mellitus**; Infections 40, 15

**Diabetes mellitus**; Insulin absorption; Insulin therapy; Treatment 40, 39

**Diabetes mellitus type 2**; Urinary albumin excretion; Coronary heart disease; Diabetic retinopathy 40, 45

**Diabetes**; Neuropathy; Paranode; Ion channel barrier; N-CAM; SAM; Polysialic acid 40, 153



- Diabetes;** Streptozotocin; *Momordica charantia* juice; Rat 40, 145
- Diabetic retinopathy;** Diabetes mellitus type 2; Urinary albumin excretion; Coronary heart disease 40, 45
- Dipper;** Type 2 diabetes mellitus; Normotension; Microalbuminuria; Blood pressure monitoring; Non-dipper 40, 161
- Efficacy;** Acarbose; Safety; Type 2 diabetes; Surveillance 40, 63
- Ethnic groups;** Childhood growth; Intrauterine environment; NIDDM 40, 137
- GAD65Ab;** Genotype; HLA-DR; HLA-DQ; Type 1 diabetes; Proliferative retinopathy 40, 9
- Genotype;** GAD65Ab; HLA-DR; HLA-DQ; Type 1 diabetes; Proliferative retinopathy 40, 9
- Glucocorticoid;** Hypoglycemia; Insulin; Thymocyte; Apoptosis 40, 1
- Glucose tolerance;** Cardiovascular risk factors; Insulin; Insulin resistance; Proinsulin 40, 81
- Glutamic acid decarboxylase;** IDDM; Th-lymphocytes; IFN- $\gamma$ ; IL-4; mRNA 40, 21
- Glycated haemoglobin;** Diabetes; Method comparison; Tanzania 40, 123
- Graves' disease;** Carbimazole; Insulin autoantibodies; Asian Indians 40, 201
- Healthy subjects;** Cerebral blood flow; Hypoglycemia recovery 40, 91
- HLA-DQ;** GAD65Ab; Genotype; HLA-DR; Type 1 diabetes; Proliferative retinopathy 40, 9
- HLA-DR;** GAD65Ab; Genotype; HLA-DQ; Type 1 diabetes; Proliferative retinopathy 40, 9
- Human atrial appendage;** Diabetes;  $\beta$ -Adrenoceptors; Rat right atria 40, 113
- Hyperinsulinemia;** Multiple risk factors; Cardiovascular disease 40, 181
- Hypoglycemia awareness;** Type 1 diabetes; Teaching and treatment program; Blood glucose perception; Blood glucose estimation 40, 129
- Hypoglycemia;** Insulin; Thymocyte; Apoptosis; Glucocorticoid 40, 1
- Hypoglycemia recovery;** Cerebral blood flow; Healthy subjects 40, 91
- IDDM;** CSII; Intensive insulin therapy; Blood glucose control 40, 175
- IDDM;** Th-lymphocytes; IFN- $\gamma$ ; IL-4; mRNA; Glutamic acid decarboxylase 40, 21
- IFN- $\gamma$ ;** IDDM; Th-lymphocytes; IL-4; mRNA; Glutamic acid decarboxylase 40, 21
- IL-4;** IDDM; Th-lymphocytes; IFN- $\gamma$ ; mRNA; Glutamic acid decarboxylase 40, 21
- Infections;** Diabetes mellitus 40, 15
- Insulin absorption;** Insulin therapy; Diabetes mellitus; Treatment 40, 39
- Insulin autoantibodies;** Graves' disease; Carbimazole; Asian Indians 40, 201
- Insulin;** Glucose tolerance; Cardiovascular risk factors; Insulin resistance; Proinsulin 40, 81
- Insulin;** Hypoglycemia; Thymocyte; Apoptosis; Glucocorticoid 40, 1
- Insulin resistance;** Glucose tolerance; Cardiovascular risk factors; Insulin; Proinsulin 40, 81
- Insulin resistance syndrome;** Microalbuminuria; Atherosclerotic risk factors 40, 191
- Insulin therapy;** Insulin absorption; Diabetes mellitus; Treatment 40, 39
- Intensive insulin therapy;** IDDM; CSII; Blood glucose control 40, 175
- Intrauterine environment;** Childhood growth; Ethnic groups; NIDDM 40, 137
- Ion channel barrier;** Neuropathy; Diabetes; Paranode; NCAM; SAM; Polysialic acid 40, 153
- Method comparison;** Diabetes; Glycated haemoglobin; Tanzania 40, 123
- Microalbuminuria;** Atherosclerotic risk factors; Insulin resistance syndrome 40, 191
- Microalbuminuria;** Type 2 diabetes mellitus; Normotension; Blood pressure monitoring; Dipper; Non-dipper 40, 161
- Momordica charantia* juice;** Diabetes; Streptozotocin; Rat 40, 145

- Motor nerve conduction velocity;** Aldose reductase inhibitor; Nitric oxide; Sciatic nerve blood flow 40, 101
- mRNA;** IDDM; Th-lymphocytes; IFN- $\gamma$ ; IL-4; Glutamic acid decarboxylase 40, 21
- Multiple risk factors;** Hyperinsulinemia; Cardiovascular disease 40, 181
- N-CAM;** Neuropathy; Diabetes; Paranode; Ion channel barrier; SAM; Polysialic acid 40, 153
- Neuropathy;** Diabetes; Paranode; Ion channel barrier; N-CAM; SAM; Polysialic acid 40, 153
- NIDDM;** Childhood growth; Ethnic groups; Intrauterine environment 40, 137
- Nitric oxide;** Aldose reductase inhibitor; Motor nerve conduction velocity; Sciatic nerve blood flow 40, 101
- Non-dipper;** Type 2 diabetes mellitus; Normotension; Microalbuminuria; Blood pressure monitoring; Dipper 40, 161
- Normotension;** Type 2 diabetes mellitus; Microalbuminuria; Blood pressure monitoring; Dipper; Non-dipper 40, 161
- One-repetition maximum strength testing;** Self-blood glucose monitoring; Resistance exercise 40, 53
- Osteocalcin;** Bone turnover; Deoxypyridinoline; Diabetes 40, 75
- Osteopenia;** Bone mineral density; Type 1 diabetes 40, 31
- Outcomes;** Type 2 diabetes; Retinopathy 40, 167
- Paranode;** Neuropathy; Diabetes; Ion channel barrier; N-CAM; SAM; Polysialic acid 40, 153
- Polysialic acid;** Neuropathy; Diabetes; Paranode; Ion channel barrier; N-CAM; SAM 40, 153
- Proinsulin;** Glucose tolerance; Cardiovascular risk factors; Insulin; Insulin resistance 40, 81
- Proliferative retinopathy;** GAD65Ab; Genotype; HLA-DR; HLA-DQ; Type 1 diabetes 40, 9
- Rat;** Diabetes; Streptozotocin; *Momordica charantia* juice 40, 145
- Rat right atria;** Diabetes;  $\beta$ -Adrenoceptors; Human atrial appendage 40, 113
- Resistance exercise;** Self-blood glucose monitoring; One-repetition maximum strength testing 40, 53
- Retinopathy;** Type 2 diabetes; Outcomes 40, 167
- Safety;** Acarbose; Efficacy; Type 2 diabetes; Surveillance 40, 63
- SAM;** Neuropathy; Diabetes; Paranode; Ion channel barrier; N-CAM; Polysialic acid 40, 153
- Sciatic nerve blood flow;** Aldose reductase inhibitor; Motor nerve conduction velocity; Nitric oxide 40, 101
- Self-blood glucose monitoring;** Resistance exercise; One-repetition maximum strength testing 40, 53
- Streptozotocin;** Diabetes; *Momordica charantia* juice; Rat 40, 145
- Surveillance;** Acarbose; Efficacy; Safety; Type 2 diabetes 40, 63
- Tanzania;** Diabetes; Glycated haemoglobin; Method comparison 40, 123
- Teaching and treatment program;** Type 1 diabetes; Blood glucose perception; Blood glucose estimation; Hypoglycemia awareness 40, 129
- Th-lymphocytes;** IDDM; IFN- $\gamma$ ; IL-4; mRNA; Glutamic acid decarboxylase 40, 21
- Thymocyte;** Hypoglycemia; Insulin; Apoptosis; Glucocorticoid 40, 1
- Treatment;** Insulin absorption; Insulin therapy; Diabetes mellitus 40, 39
- Type 2 diabetes;** Acarbose; Efficacy; Safety; Surveillance 40, 63
- Type 1 diabetes;** Bone mineral density; Osteopenia 40, 31
- Type 1 diabetes;** GAD65Ab; Genotype; HLA-DR; HLA-DQ; Proliferative retinopathy 40, 9
- Type 2 diabetes mellitus;** Normotension; Microalbuminuria; Blood pressure monitoring; Dipper; Non-dipper 40, 161
- Type 2 diabetes;** Outcomes; Retinopathy 40, 167
- Type 1 diabetes;** Teaching and treatment program; Blood glucose perception; Blood glucose estimation; Hypoglycemia awareness 40, 129
- Urinary albumin excretion;** Diabetes mellitus type 2; Coronary heart disease; Diabetic retinopathy 40, 45

